Affinity Asset Advisors LLC Increases Holdings in Insmed, Inc. $INSM

Affinity Asset Advisors LLC grew its position in Insmed, Inc. (NASDAQ:INSM) by 239.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 475,000 shares of the biopharmaceutical company’s stock after buying an additional 335,000 shares during the period. Insmed accounts for approximately 6.5% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 2nd largest holding. Affinity Asset Advisors LLC owned approximately 0.22% of Insmed worth $47,804,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock valued at $1,393,675,000 after acquiring an additional 49,149 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Insmed by 1.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after purchasing an additional 219,131 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock valued at $262,967,000 after purchasing an additional 1,799,382 shares during the period. Artisan Partners Limited Partnership boosted its stake in shares of Insmed by 3.0% in the 2nd quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock valued at $333,555,000 after purchasing an additional 97,073 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Insmed by 2.5% in the 1st quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after purchasing an additional 59,952 shares during the last quarter.

Insider Buying and Selling at Insmed

In related news, Director Elizabeth M. Anderson sold 5,000 shares of the stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $204.58, for a total transaction of $1,022,900.00. Following the completion of the transaction, the director directly owned 58,729 shares in the company, valued at approximately $12,014,778.82. This trade represents a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of Insmed stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total transaction of $4,985,951.40. Following the completion of the sale, the insider owned 54,902 shares in the company, valued at $10,089,889.56. The trade was a 33.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 233,650 shares of company stock valued at $41,063,785 over the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Wells Fargo & Company increased their price objective on shares of Insmed from $171.00 to $217.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Stifel Nicolaus upped their target price on shares of Insmed from $121.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, August 14th. TD Cowen increased their price target on Insmed from $223.00 to $231.00 and gave the company a “buy” rating in a research note on Thursday, November 20th. The Goldman Sachs Group lifted their price objective on Insmed from $196.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, JPMorgan Chase & Co. upped their price objective on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Twenty research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $187.89.

Insmed Price Performance

Shares of INSM opened at $204.00 on Friday. The stock has a 50 day simple moving average of $180.50 and a 200 day simple moving average of $134.48. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The firm has a market capitalization of $43.51 billion, a PE ratio of -32.96 and a beta of 1.01.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The company had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same quarter last year, the business posted ($1.27) earnings per share. The business’s quarterly revenue was up 52.4% on a year-over-year basis. Sell-side analysts predict that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.